{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:29:23Z","timestamp":1783492163884,"version":"3.55.0"},"reference-count":70,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>No single effective therapy for alcohol abuse has been found, despite it being a serious sociological and economic problem for hundreds of years. It seems difficult to find a single drug as a panacea for the alcohol problem due to the complexity of the pathophysiology of alcohol dependence. The purpose of this narrative review is to review existing and potentially future pharmaceuticals for the treatment of alcohol dependence in the most affordable way possible. Psychotherapy is the mainstay of treatment for alcoholism, while few drugs approved by legislators are available in the augmentation of this treatment, such as acamprosate, disulfiram, and naltrexone, approved by the FDA, and nalmefene by the EMA. There are recent reports in the literature on the possibility of using baclofen, topiramate, varenicline, and gabapentin in the treatment of alcohol dependence. Moreover, the results of recent clinical trials using psychoactive substances such as psilocybin and MDMA appear to be a breakthrough in the modern treatment of alcohol abuse. Despite this initial optimism, a lot of scientific effort is still needed before new pharmacological methods supporting the treatment of alcohol dependence syndrome will be widely available.<\/jats:p>","DOI":"10.3390\/ijerph20031870","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T06:22:10Z","timestamp":1674109330000},"page":"1870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Medications for the Treatment of Alcohol Dependence\u2014Current State of Knowledge and Future Perspectives from a Public Health Perspective"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7283-5491","authenticated-orcid":false,"given":"Iga","family":"Stok\u0142osa","sequence":"first","affiliation":[{"name":"Department and Clinic of Psychiatry, Medical University of Silesia, 42-612 Tarnowskie G\u00f3ry, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-393X","authenticated-orcid":false,"given":"Gniewko","family":"Wi\u0119ckiewicz","sequence":"additional","affiliation":[{"name":"Department and Clinic of Psychiatry, Medical University of Silesia, 42-612 Tarnowskie G\u00f3ry, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0105-5401","authenticated-orcid":false,"given":"Maciej","family":"Stok\u0142osa","sequence":"additional","affiliation":[{"name":"Department and Clinic of Psychiatry, Medical University of Silesia, 42-612 Tarnowskie G\u00f3ry, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8009-7118","authenticated-orcid":false,"given":"Magdalena","family":"Piegza","sequence":"additional","affiliation":[{"name":"Department and Clinic of Psychiatry, Medical University of Silesia, 42-612 Tarnowskie G\u00f3ry, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-0063","authenticated-orcid":false,"given":"Robert","family":"Pudlo","sequence":"additional","affiliation":[{"name":"Department and Clinic of Psychiatry, Medical University of Silesia, 42-612 Tarnowskie G\u00f3ry, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Gorczyca","sequence":"additional","affiliation":[{"name":"Department and Clinic of Psychiatry, Medical University of Silesia, 42-612 Tarnowskie G\u00f3ry, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"ref_1","unstructured":"(2022, December 12). Alcohol\u2013World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/alcohol."},{"key":"ref_2","unstructured":"(2022, December 12). Alcohol Facts and Statistics, Available online: https:\/\/www.niaaa.nih.gov\/publications\/brochures-and-fact-sheets\/alcohol-facts-and-statistics."},{"key":"ref_3","first-page":"301","article-title":"Alcohol Dependence and Harmful Use of Alcohol","volume":"113","author":"Batra","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40273-021-01031-8","article-title":"What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study","volume":"39","author":"Manthey","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"ref_5","first-page":"e1","article-title":"Alcohol\u2019s effects on the cardiovascular system","volume":"38","author":"Piano","year":"2017","journal-title":"Alcohol Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1080\/10408398.2021.1911928","article-title":"The role of alcohol consumption in pathogenesis of gout","volume":"62","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_7","unstructured":"(2022, December 12). Global Status Report on Alcohol and Health 2018. Available online: https:\/\/www.who.int\/substance_abuse\/publications\/global_alcohol_report\/en\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/add.14404","article-title":"A systematic review of the next-day effects of heavy alcohol consumption on cognitive performance","volume":"113","author":"Gunn","year":"2018","journal-title":"Addiction"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2016.01.003","article-title":"Peer-Delivered Recovery Support Services for Addictions in the United States: A Systematic Review","volume":"63","author":"Bassuk","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0740-5472(01)00210-0","article-title":"Reduced-risk drinking as a treatment goal: What clinicians need to know","volume":"22","author":"Ambrogne","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/YCO.0000000000000512","article-title":"Selecting an appropriate alcohol pharmacotherapy: Review of recent findings","volume":"32","author":"Alho","year":"2019","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_14","first-page":"77","article-title":"Animal models in alcohol research","volume":"24","author":"Tabakoff","year":"2000","journal-title":"Alcohol Res. Health."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/bs.irn.2016.02.006","article-title":"An Animal Model of Alcohol Dependence to Screen Medications for Treating Alcoholism","volume":"126","author":"Becker","year":"2016","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.31887\/DCNS.2017.19.3\/rspanagel","article-title":"Animal models of addiction","volume":"19","author":"Spanagel","year":"2022","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4103\/psychiatry.IndianJPsychiatry_201_19","article-title":"A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence","volume":"62","author":"Kumar","year":"2020","journal-title":"Indian J. Psychiatry"},{"key":"ref_18","unstructured":"(2022, December 12). CAMPRAL\u00ae (Acamprosate Calcium) Delayed-Release Tablets. US Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021431s013lbl.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/ADM.0b013e318156c26f","article-title":"Acamprosate in Alcohol Dependence: Implications of a Unique Mechanism of Action","volume":"1","author":"Littleton","year":"2007","journal-title":"J. Addict. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1530-0277.2011.01616.x","article-title":"Acamprosate for alcohol dependence: A sex-specific meta-analysis based on individual patient data","volume":"36","author":"Mason","year":"2012","journal-title":"Alcohol Clin. Exp. Res."},{"key":"ref_22","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","volume":"9","author":"Leucht","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-015-0423-9","article-title":"Acamprosate: A Review of Its Use in Alcohol Dependence","volume":"75","author":"PLoSker","year":"2015","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Naudet, F., Palpacuer, C., Boussageon, R., and Laviolle, B. (2016). Evaluation in alcohol use disorders\u2013insights from the nalmefene experience. BMC Med., 14.","DOI":"10.1186\/s12916-016-0664-9"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/YIC.0000000000000170","article-title":"Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: A preliminary report","volume":"32","author":"Patrizi","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/j.eurpsy.2017.01.1756","article-title":"Nalmefene effectiveness in reducing alcohol consumption and prevention of craving: A case report","volume":"41","author":"Landera","year":"2017","journal-title":"Eur. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: A review of its use in the treatment of alcohol dependence","volume":"27","author":"Keating","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40261-017-0590-4","article-title":"Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results","volume":"38","author":"Barrio","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s12325-017-0546-3","article-title":"Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study","volume":"34","author":"Martinotti","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109365","DOI":"10.1016\/j.drugalcdep.2022.109365","article-title":"Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis","volume":"233","author":"Hashimoto","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"De Sousa, A. (2019). Disulfiram: Pharmacology and Mechanism of Action. Disulfiram, Springer.","DOI":"10.1007\/978-981-32-9876-7"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.15288\/jsads.2014.75.79","article-title":"Pharmacotherapy of alcohol use disorders: Seventy-five years of progress","volume":"75","author":"Zindel","year":"2014","journal-title":"J. Stud. Alcohol Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Skinner, M.D., Lahmek, P., Pham, H., and Aubin, H.J. (2014). Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087366"},{"key":"ref_34","first-page":"457","article-title":"Medications for Alcohol Use Disorder","volume":"93","author":"Winslow","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"ref_35","unstructured":"Agency for Healthcare Research and Quality (2022, December 12). Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings. Executive Summary, Available online: http:\/\/effectivehealthcare.ahrq.gov\/ehc\/products\/477\/1907\/alcohol-misuse-drug-therapy-executive-140513.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1192\/bjp.129.3.277","article-title":"Disulfiram implantation: Placebo, psychological deterrent, and pharmacological deterrent effects","volume":"129","author":"Wilson","year":"1976","journal-title":"Br. J. Psychiatry."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"De Sousa, A. (2019). Disulfiram in the Management of Alcohol Dependence. Disulfiram, Springer.","DOI":"10.1007\/978-981-32-9876-7"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: A half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/adb.12747","article-title":"Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis","volume":"24","author":"Ray","year":"2019","journal-title":"Addict. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13181-015-0512-x","article-title":"Naltrexone: Not Just for Opioids Anymore","volume":"12","author":"Sudakin","year":"2016","journal-title":"J. Med. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.jaad.2018.12.031","article-title":"The uses of naltrexone in dermatologic conditions","volume":"80","author":"Lee","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13011-020-00266-6","article-title":"Effectiveness of naltrexone treatment for alcohol use disorders in HIV: A systematic review","volume":"15","author":"Farhadian","year":"2020","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"392","DOI":"10.9740\/mhc.2019.11.392","article-title":"Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans","volume":"9","author":"Leighty","year":"2019","journal-title":"Ment. Health Clin."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2340\/16501977-2211","article-title":"Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen","volume":"49","author":"Ertzgaard","year":"2017","journal-title":"J. Rehabil. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187152710790966614","article-title":"Effectiveness and safety of baclofen in the treatment of alcohol dependent patients","volume":"9","author":"Leggio","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_47","first-page":"1122","article-title":"Le baclof\u00e8ne dans le traitement de la d\u00e9pendance \u00e0 l\u2019alcool: Une saga fran\u00e7aise [Baclofen in the treatment of alcohol addiction: A French saga]","volume":"17","author":"Paille","year":"2021","journal-title":"Rev. Med. Suisse."},{"key":"ref_48","first-page":"CD012557","article-title":"Baclofen for alcohol use disorder","volume":"11","author":"Minozzi","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fpsyt.2018.00367","article-title":"Safety Challenges of Using High Dose Baclofen for Alcohol Use Disorder: A Focused Review","volume":"22","author":"Rolland","year":"2018","journal-title":"Front. Psychiatry."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/bs.podrm.2018.11.005","article-title":"Topiramate: Comprehensive profile","volume":"44","author":"Khalil","year":"2019","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1017\/S0317167100034855","article-title":"Topiramate-safety and tolerability","volume":"25","author":"Jones","year":"1998","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/ADM.0000000000000443","article-title":"Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review","volume":"13","author":"Manhapra","year":"2019","journal-title":"J. Addict. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12518","DOI":"10.1073\/pnas.0705368104","article-title":"Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking","volume":"24","author":"Steensland","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biopsych.2009.01.029","article-title":"Varenicline reduces alcohol self-administration in heavy-drinking smokers","volume":"66","author":"McKee","year":"2009","journal-title":"Biol. Psychiatry."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","article-title":"Gabapentin for the treatment of alcohol use disorder","volume":"27","author":"Mason","year":"2018","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.46747\/cfp.6704269","article-title":"Gabapentin for alcohol use disorder","volume":"67","author":"Weresch","year":"2021","journal-title":"Can. Fam. Physician"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wi\u0119ckiewicz, G., Stok\u0142osa, I., Piegza, M., Gorczyca, P., and Pudlo, R. (2021). Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080793"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"106976","DOI":"10.1016\/j.cct.2022.106976","article-title":"Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial","volume":"123","author":"Mennenga","year":"2022","journal-title":"Contemp. Clin. Trials."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.12740\/PP\/OnlineFirst\/134317","article-title":"Demographic and health characteristics of 3,4-methylenedioxymethamphetamine users (MDMA, ecstasy)","volume":"56","author":"Danel","year":"2022","journal-title":"Psychiatr. Polska"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.12740\/PP\/OnlineFirst\/133919","article-title":"Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review","volume":"56","author":"Szafoni","year":"2022","journal-title":"Psychiatr. Polska"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neuropharm.2017.11.004","article-title":"Why MDMA therapy for alcohol use disorder? And why now?","volume":"142","author":"Sessa","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109356","DOI":"10.1016\/j.drugalcdep.2022.109356","article-title":"The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD","volume":"233","author":"Nicholas","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0741-8329(00)00137-3","article-title":"Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption","volume":"23","author":"Stromberg","year":"2001","journal-title":"Alcohol"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13974","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: A systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","volume":"13","author":"Palpacuer","year":"2018","journal-title":"Addiction"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000371547","article-title":"Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients","volume":"21","author":"Aubin","year":"2015","journal-title":"Eur. Addict. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e011045","DOI":"10.1136\/bmjopen-2016-011045","article-title":"Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers","volume":"6","author":"Chaiton","year":"2016","journal-title":"BMJ Open"},{"key":"ref_69","first-page":"228","article-title":"Barriers and solutions to addressing tobacco dependence in addiction treatment programs","volume":"29","author":"Ziedonis","year":"2006","journal-title":"Alcohol Res. Health"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S2215-0366(19)30213-5","article-title":"Prevention, screening, and treatment for heavy drinking and alcohol use disorder","volume":"6","author":"Knox","year":"2019","journal-title":"Lancet Psychiatry"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/3\/1870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:10:36Z","timestamp":1760119836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/3\/1870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijerph20031870"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20031870","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}